The COPD Foundation has launched the COPD360Net project to facilitate, assess, and accelerate clinical trials to further the development and approval of novel digital health tools and treatments for chronic obstructive pulmonary disease (COPD). The project is being launched before November, which is COPD Awareness Month,…
News
Verona Pharma has launched two Phase 3 trials to assess the safety and effectiveness of ensifentrine, its investigational inhalation treatment for chronic obstructive pulmonary disease (COPD). The trials — called ENHANCE-1 (NCT04535986) and ENHANCE-2 (NCT04542057) — are each expected to enroll up to 800 patients…
Chronic obstructive pulmonary disease (COPD) is more prevalent than previously thought and associated with a mortality rate that is likely higher than earlier estimates, a review study has found. Invasive aspergillosis — a respiratory infection caused by molds belonging to the Aspergillus genus — may be a…
PAO Group and Puration have entered a new agreement that will allow PAO Group to build a proprietary hemp cultivar development facility on Puration’s branded site in Farmersville, Texas, according to a press release. The new facility is expected to help provide materials to further the development of…
Nebulized ensifentrine (RPL554) — which works both to widen the airways and as an anti-inflammatory — showed a significant early effect on breathlessness in people with chronic obstructive pulmonary disease (COPD), according to the therapy’s developer, Verona Pharma. Apart from easing breathlessness, in four weeks of treatment…
News
SNG001 Can Safely Improve Lung Function in COPD Patients With Viral Infections, Interim Data Show
Synairgen‘s anti-viral therapy SNG001 has a good safety profile in people with chronic obstructive pulmonary disease (COPD), Phase 2 trial data show. The data also indicate that SNG001 induces its intended anti-viral effect, and that it improves lung function in COPD patients with viral lung infections. “These…
Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) outperformed Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in reducing the rate of moderate or severe exacerbations in people with chronic obstructive pulmonary disease (COPD) during all seasons of the year, new data from the ETHOS clinical trial show. That data will be presented by…
News
Low-dose Morphine Improves Health in COPD Patients With Shortness of Breath, Phase 4 Trial Suggests
Regular, low-dose oral morphine led to significant health improvements in adults with advanced chronic obstructive pulmonary disease (COPD) who regularly experienced shortness of breath, according to results of a Phase 4 clinical trial. Treatment with morphine did not cause lung-related…
Men with moderate-to-severe chronic obstructive pulmonary disease (COPD) who drank a beverage composed of whey protein fortified with magnesium and vitamin C had lower levels of the inflammation-associated protein interleukin-6 in their blood, compared to those who did not receive the beverage,…
A blood test to measure levels of the immune signaling protein interleukin-32 (IL-32) may be a useful biomarker to diagnose and assess the severity of chronic obstructive pulmonary disease (COPD), a new study suggests. The study, “…
Recent Posts
- US study names COPD therapy Anoro Elipta top choice for new patients
- Applying wise old sayings to a different body with COPD
- I maintain my morning rituals to keep COPD from shrinking my world
- Living with COPD isn’t a test that I have to pass
- Mucus-based test shows promise for measuring health of lungs in COPD